Blocking ISS-N1 with low concentrations of antisense oligonucleotide (ASO) effectively increased SMN protein levels in studies in mouse models or fibroblasts collected from SMA patients. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.